Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cleary

Showing results (301-310 of 334) with videos related to

Pageof 34
Sort By:
Cancer Cell|April 5, 2003
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBPKenji Deguchi, Paul M Ayton, Melina Carapeti, et al.
Cell Stem Cell|February 10, 2009
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cellsTim C P Somervaille, Christina J Matheny, Gary J Spencer, et al.
Blood Advances|October 5, 2019
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cellsJohan Jeong, Astraea Jager, Pablo Domizi, et al.
Blood|August 28, 2015
MLL leukemia induction by genome editing of human CD34+ hematopoietic cellsCorina Buechele, Erin H Breese, Dominik Schneidawind, et al.
Journal of Medicinal Chemistry|October 16, 1992
Growth hormone-releasing factor analogs with hydrophobic residues at position 19. Effects on growth hormone releasing activity in vitro and in vivo, stability in blood plasma in vitro, and secondary structureA R Friedman, A K Ichhpurani, W M Moseley, et al.
Journal of Medicinal Chemistry|April 2, 1993
Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivityT M Kubiak, A R Friedman, R A Martin, et al.
Blood Advances|March 6, 2019
Identification of enhancer of mRNA decapping 4 as a novel fusion partner of <i>MLL</i> in acute myeloid leukemiaHeiko Becker, Gabriele Greve, Keisuke Kataoka, et al.
Cancer Cell|September 24, 2013
Epigenetic roles of MLL oncoproteins are dependent on NF-κBHsu-Ping Kuo, Zhong Wang, Dung-Fang Lee, et al.
Molecular Medicine (Cambridge, Mass.)|May 22, 2023
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversionElizabeth J Wilk, Timothy C Howton, Jennifer L Fisher, et al.
Oncogene|May 3, 2006
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcriptionE Reed-Inderbitzin, I Moreno-Miralles, S K Vanden-Eynden, et al.
Pageof 34

Showing results (301-310 of 334) with videos related to

Sort By:
Pageof 34
Cancer Cell|April 5, 2003
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBPKenji Deguchi, Paul M Ayton, Melina Carapeti, et al.
Cell Stem Cell|February 10, 2009
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cellsTim C P Somervaille, Christina J Matheny, Gary J Spencer, et al.
Blood Advances|October 5, 2019
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cellsJohan Jeong, Astraea Jager, Pablo Domizi, et al.
Blood|August 28, 2015
MLL leukemia induction by genome editing of human CD34+ hematopoietic cellsCorina Buechele, Erin H Breese, Dominik Schneidawind, et al.
Journal of Medicinal Chemistry|October 16, 1992
Growth hormone-releasing factor analogs with hydrophobic residues at position 19. Effects on growth hormone releasing activity in vitro and in vivo, stability in blood plasma in vitro, and secondary structureA R Friedman, A K Ichhpurani, W M Moseley, et al.
Journal of Medicinal Chemistry|April 2, 1993
Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivityT M Kubiak, A R Friedman, R A Martin, et al.
Blood Advances|March 6, 2019
Identification of enhancer of mRNA decapping 4 as a novel fusion partner of <i>MLL</i> in acute myeloid leukemiaHeiko Becker, Gabriele Greve, Keisuke Kataoka, et al.
Cancer Cell|September 24, 2013
Epigenetic roles of MLL oncoproteins are dependent on NF-κBHsu-Ping Kuo, Zhong Wang, Dung-Fang Lee, et al.
Molecular Medicine (Cambridge, Mass.)|May 22, 2023
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversionElizabeth J Wilk, Timothy C Howton, Jennifer L Fisher, et al.
Oncogene|May 3, 2006
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcriptionE Reed-Inderbitzin, I Moreno-Miralles, S K Vanden-Eynden, et al.
Pageof 34